Mode
Text Size
Log in / Sign up

Systematic review and meta-analysis of oxidative stress biomarkers in older adults with T2DM or Parkinson's diseaseParkinson’s and Diabetes Linked by Hidden Body Damage

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note markedly elevated oxidative stress biomarkers in T2DM and PD, but interpret findings cautiously due to high heterogeneity.

This systematic review and meta-analysis assessed oxidative stress biomarkers in serum, plasma, or leukocytes across 7,521 human subjects aged ≥ 50 years, comprising 3,522 with type 2 diabetes mellitus (T2DM), 722 with Parkinson's disease (PD), and 3,277 controls. The primary outcomes measured standardized differences (Hedges' g) for F2-isoprostanes and 8-OHdG to compare patient groups against controls.

In the T2DM population, F2-isoprostanes were markedly elevated with an effect size of 1.60 (95% CI: 0.95-2.25). Similarly, 8-OHdG levels were markedly elevated in T2DM, showing an effect size of 2.64 (95% CI: 2.13-3.14). When examining T2DM patients with nephropathy, 8-OHdG indicated extreme oxidative stress with an effect size of 5.24.

In the PD cohort, 8-OHdG was moderately elevated with an effect size of 0.78 (95% CI: 0.18-1.39; p = 0.011). Conversely, F2-isoprostanes in PD were not significantly elevated, with an effect size of 0.47 (95% CI: -0.43-1.38). The authors noted high heterogeneity in T2DM (I > 90%), reflecting methodological variability.

Safety data, including adverse events and tolerability, were not reported. The findings suggest associations between specific biomarkers and disease states but do not establish causality. Practice relevance regarding clinical utility remains uncertain given the observational nature of the data and reported limitations.

  • Oxidative stress markers are high in both diseases — but differently
  • Could help patients with Parkinson’s and type 2 diabetes
  • Not ready for clinics — still in research phase

This study reveals how two common diseases may fuel each other.

You wake up stiff. Your hands tremble as you reach for your morning coffee. You’ve had type 2 diabetes for years, and now, new symptoms are creeping in. Could one problem be making the other worse?

New research says yes — and it all comes down to invisible damage happening inside your cells.

Millions of people live with type 2 diabetes. Millions also face Parkinson’s disease. But when both show up in the same person, care gets harder. Symptoms worsen. Treatments don’t work as well.

And doctors have long wondered — is there a hidden link?

Oxidative stress is a key suspect. It’s what happens when your body’s cells get worn down by harmful molecules. Think of it like rust inside your body. Over time, it damages tissues, organs, and even DNA.

This kind of stress is known to play a role in both diseases. But until now, we didn’t know how the two might share the same biological path.

The Surprising Shift

For years, scientists assumed both diseases showed the same signs of cellular damage. They looked for two key markers:

  • F2-isoprostanes (a sign of fat damage in cell walls)
  • 8-OHdG (a sign of DNA damage)

They thought both would be high in both diseases.

But here’s the twist: they’re not.

In type 2 diabetes, both markers are sky-high. That’s expected. The body struggles to manage sugar, which fuels oxidative stress.

In Parkinson’s, only one marker — 8-OHdG — is clearly elevated. The other, F2-isoprostanes, shows no clear rise.

This means the kind of cell damage in Parkinson’s may be more focused — hitting DNA harder than fats.

What This Changes

This isn’t just academic. It suggests that when someone has both diseases, the real danger may come from shared DNA damage.

And that could explain why patients with both conditions often decline faster.

It also means we might one day use 8-OHdG as a warning sign — a blood test that shows who’s at risk before symptoms get worse.

Imagine your cells are like cars running all day. Over time, the engine builds up exhaust — harmful byproducts.

In a healthy body, cleanup crews (antioxidants) remove the exhaust.

But in diabetes and Parkinson’s, the cleanup slows. The exhaust builds up.

That exhaust is oxidative stress.

Now, think of F2-isoprostanes as smoke coming from the engine (damaged fats). 8-OHdG is like cracks in the engine block (broken DNA).

In diabetes, both smoke and cracks appear. In Parkinson’s, the smoke isn’t always visible — but the cracks are there.

This tells us Parkinson’s may cause deeper, more hidden damage — especially when diabetes is also present.

Researchers looked at 54 studies involving over 7,500 people aged 50 and older. Some had type 2 diabetes. Some had Parkinson’s. Others were healthy controls.

They checked blood or cell samples for the two oxidative stress markers.

Using advanced analysis, they compared levels across groups — and dug into what might affect results, like age, sample type, and disease complications.

In type 2 diabetes, both markers were strongly elevated.

  • 8-OHdG was 2.6 times higher than in healthy people.
  • F2-isoprostanes were 1.6 times higher.

Patients with kidney damage (a common diabetes complication) showed even higher levels — up to 5 times more damage.

In Parkinson’s, only 8-OHdG was clearly raised — about 78% higher than controls. F2-isoprostanes showed no significant increase.

The strongest signals came from plasma (liquid part of blood) and studies using strict trial designs.

This doesn’t mean this treatment is available yet.

But there’s a catch.

The data on Parkinson’s is less consistent. Some studies showed high F2-isoprostanes; others didn’t. This may be due to differences in how samples were handled or tested.

Also, most studies measured these markers in blood — but Parkinson’s mainly affects the brain. Blood levels might not tell the whole story.

Still, the clear rise in 8-OHdG suggests DNA damage is a real player — especially when diabetes is also in the mix.

This study doesn’t prove one disease causes the other. But it shows they may feed off the same kind of internal damage — like two fires sharing the same fuel.

The fact that 8-OHdG rises in both points to DNA stress as a possible link.

It also highlights the need for better, more consistent testing methods. Right now, labs measure these markers in different ways — making comparisons hard.

Standardizing tests could one day help doctors spot high-risk patients earlier.

If you or a loved one has type 2 diabetes, Parkinson’s, or both — this research won’t change your care today.

There’s no new test or treatment yet.

But it adds strong evidence that managing oxidative stress could be key — especially through proven steps like:

  • Eating antioxidant-rich foods (berries, greens, nuts)
  • Staying physically active
  • Controlling blood sugar
  • Avoiding smoking and excess alcohol

Talk to your doctor about reducing overall stress on your body. Some supplements (like CoQ10 or vitamin E) are being studied, but none are proven for this use.

The Limits

This study combined past research — it didn’t test patients directly. Most data came from blood samples, not brain tissue. And the Parkinson’s group had fewer studies, making results less certain.

Also, all data is from people already diagnosed. We don’t yet know if these markers can predict disease before symptoms start.

What’s Next

Scientists now need to track people over time — measuring these markers before and after diagnosis.

They also need standardized lab methods to make results more reliable.

One day, a simple blood test might help identify those at risk for both diseases — and guide treatments to slow both.

But that future is still years away.

For now, the message is clear: the body’s internal environment matters. And protecting your cells may protect your brain — especially if you’re already managing diabetes.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedDec 2026
View Original Abstract ↓
BACKGROUND: Oxidative stress is central to type 2 diabetes mellitus (T2DM) and Parkinson's disease (PD). However, the utility of biomarkers for lipid peroxidation (F2-isoprostanes) and DNA damage (8-OHdG) in the comorbidity of PD and T2DM remains unclear. METHODS: We conducted a systematic review and meta-analysis of 54 unique studies of human subjects aged ≥ 50 years ( = 7,521: 3,522 with T2DM, 722 with PD, and 3,277 controls), measuring biomarkers in serum, plasma, or leukocytes. Mixed-effects models quantified standardized differences (Hedges' g) across subgroups. RESULTS: In T2DM, F2-isoprostanes ( = 1.60, 95% CI: 0.95-2.25) and 8-OHdG ( = 2.64, 95% CI: 2.13-3.14) were markedly elevated ( < 0.001). Stronger effects were observed in younger cohorts and serum/plasma samples, with complications like nephropathy exhibiting extreme oxidative stress ( = 5.24). In PD, 8-OHdG was moderately elevated ( = 0.78, 95% CI: 0.18-1.39;  = 0.011), particularly in randomized controlled trials and plasma samples, whereas F2-isoprostanes were not significantly elevated ( = 0.47, 95% CI: -0.43-1.38). High heterogeneity in T2DM (I > 90%) reflected methodological variability. CONCLUSION: Distinct profiles - both markers elevated in T2DM but only 8-OHdG in PD - underscore 8-OHdG's potential in PD-T2DM comorbidity. Future research should focus on standardized assays, multi-compartmental or multi-modal sampling, and longitudinal studies to clarify mechanisms and therapeutic targets.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.